

BEST AVAILABLE COPY

REC'D 19 MAR 2003

WIPO

PCT

P1 973579

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

March 12, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/349,367

FILING DATE: January 22, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/02142

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



W. Montgomery
W. MONTGOMERY
Certifying Officer

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **INVENTOR(S)**

Given Name (first and middle [if any])

Family Name or Surname

Residence
(City and either State or Foreign Country)☒ Additional inventors are being named on the 1 separately numbered sheets attached hereto**TITLE OF THE INVENTION (500 characters max)***Device for INTERPOSITIONAL Arthroplasty*

Direct all correspondence to:

CORRESPONDENCE ADDRESS

Customer Number

Type Customer Number here

Place Customer Number
Bar Code Label here

OR

Firm or
Individual Name*ADVANCED BIO SURFACES, INC.*

Address

5909 BAKER ROAD

Address

SUITE 550

City

MINNETONKA

State

MN

ZIP

55345

Country

USA

Telephone

952-912-5400

Fax

*952-912-5410***ENCLOSED APPLICATION PARTS (check all that apply)**

Specification Number of Pages

5

CD(s), Number



Drawing(s) Number of Sheets

3

Other (specify)



Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

Applicant claims small entity status. See 37 CFR 1.27.



A check or money order is enclosed to cover the filing fees

The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 

Payment by credit card. Form PTO-2038 is attached.

FILING FEE
AMOUNT (\$)80.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.



No.

Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

Laurie E Lynch

TYPED or PRINTED NAME

Laurie E Lynch

TELEPHONE

(952) 979-1815

Date

1/18/02

REGISTRATION NO.

(if appropriate)

Docket Number:

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

JC92 U.S. PTO
01/22/02

60349367 012202

PTO/SB/16 (10-01)
01/22/02

PROVISIONAL APPLICATION COVER SHEET

Additional Page

PTO/SB/16 (10-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

INVENTOR(S)/APPLICANT(S)

| Given Name (first and middle (if any)) | Family or Surname | Residence (City and either State or Foreign Country) |
|--|-------------------|---|
| Laurie Ellen | Lynch | 6970 Mariann Dr Eden Prairie MN 55346 |
| ALEXANDER | ARSENYEV | 1845 TURQUOISE TRAIL EAGEN, MN 55122 |
| PAUL | BUSCEMI | 2310 TAMARACK DRIVE LONG LAKE, MN 55356 |
| KRISTIN M. | MORTENSON | 4233 STANDISH Ave. So. MINNEAPOLIS, MN 55407 |
| MARK A | RYDELL | 516 TURNPIKE ROAD GOLDEN VALLEY, MN 55416 |
| JEFFREY C | FELT | 4800 LODGE LANE EXCELSIOR, MN 55311 |

Number 1 of 1

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Device for Interpositional Arthroplasty

The present application describes the device and materials used for the creation of an interpositional arthroplasty using an implanted device fixed to support the structure of the original articulating surface and to generally conform to the shape of the original surface in a mammal. The device is intended for the end of a rotating, sliding or rolling bony surface such as in the knee, finger, hip, toe, spine, wrist, elbow, shoulder, ankle or TMJ joint. The device will function:

- a) as an insertable, conformable spacer, that separates opposing bone to restore joint alignment
- b) as an impact absorber,
- c) to reduce friction during joint motion, and/or
- d) to improve lubrication conditions between contacting surfaces.

To achieve these goals the device or one of its components is made from a soft, elastomeric material. The insertion of the device into the joint results ultimately in pain relief and improved function in patients with degenerative joint disease or injured or damaged joints.

The device provides good congruency by 1) use of soft elastomeric materials at bone contacting surfaces that conforms to bone surfaces and/or 2) use of material that can be further formed at time of insertion into the joint site.

The device may consist of a plurality of materials, such as polymers, including but not limited to polyurethanes, polyethylene, polyureas, polyacrylates, rubbers, polyurethane acrylates, hydrogels of various chemical natures, epoxies, metals, biopolymers and/or hybrids of any of the above. These materials can be plasticized, reinforced, or otherwise modified in order to change or improve certain properties.

In an alternative embodiment, the device consists of a composite of materials, which may include more wear resistant surface(s), softer, more conformable surface(s) and/or inner layer(s) that provide either cushioning or support or any combinations thereof (see figure 1). In a preferred embodiment the top surface could be a highly wear resistant polyurethane and the bottom surface could be a softer, more conformable rubber material (see figure 2). These composites can be secured together by use of glue or other means of chemical adhesion, mechanical locks, insert-molded (see figure 3) or other physical means or by the use of an interpenetrating polymer network (IPN) or any combinations thereof. Alternatively, the material could be such that it exhibits a modulus gradient from the top surface to the bottom surface.

The design optionally includes materials that can be further formed at the joint site. The entire device can consist of a formable material or one or more layers of the device materials may be formable. The methods for further forming include application of heat, pressure, or irradiation (i.e. UV, visible, IR), mixing by flexing (i.e. use of frangible seals, mixing elements – see figure 4) or chemical treatment or combinations

thereof. Examples of such materials include polymers with plasticizers or fillers, heat deformable materials, materials that further react with one another upon application of heat, light, pressure and or mixing to create a more formable material. These materials can be used in combination with the local anatomy to produce the desired shape and geometry. In general, the implants are designed for optimum fit and congruency once placed in the joint site. Multiple size implants can be made off-site and the selection of the appropriate implant size could be chosen at the time of surgery.

In a preferred embodiment the materials are further formed at the joint site by heating prior to insertion and then shaping in-vivo. Alternatively, the materials can be pre-formed ex-vivo to conform to the general joint geometry or can be custom made or further machined based on Magnetic Resonance Imaging (MRI), computer tomography (CT), x-rays or other imaging of the joint site. The implants can be made directly from the images or from stereolithographic models created from the images.

Fixation methods for the device allow it to be attached to the bony surface by protrusions or lips, geometry, sutures, glues, staples, screws, or pins and any combinations thereof or by combining materials that induce ingrowth of hard or soft tissue. Optimally the fixation method does not require any violation of the surrounding bones. The fixation occurs by the use of protrusions or lips designed into the implant that conform and/or adhere to the bony surfaces. A preferred embodiment for fixation in the medial tibial plateau of the knee joint is a posterior-mesial lip (see figure 5) for long term fixation that may optionally have an anterior suture (see figure 6) to allow short-term fixation to the surrounding soft tissue.

An alternative embodiment has optimum geometries for conformance and fixation in the lateral tibial compartment of the knee joint. Such geometries may include anterior lips or ridges, opposing wedged shaped lateral dimensions in the anterior and posterior portions, saddle shaped or flat or convex or concave dimensions in the anterior-posterior dimensions (see figure 7).

The device will be especially effective when the patient will have a diagnosis of osteoarthritis and have loss of cartilage on the articulating surface. A determination will be made of the amount of correction needed for the reestablishment of a normal angle of articulation. The ligaments will be balanced so that there is no loss of range of motion with the implant in place and the device will be placed in such a position that the eventual resulting geometry reestablishes the same plane and orientation of the original articular surface, unless some correction is necessary.

Access to the site is obtained in a minimally invasive way. In the preferred embodiment, access is accomplished both by arthroscopic means and by a mini-arthrotomy with a small incision that allows the device to be inserted into the joint without sacrificing nerves, vessels, muscles or ligaments surrounding the joint. In an alternative embodiment, this is accomplished completely through arthroscopic means with arthroscopic portals. In the preferred embodiment fibrillated articulating cartilage that is degenerated is removed down to the subchondral surface. Also the medial

meniscus is resected to the outer margin. Additional site preparation including removal of bony ridges, osteophytes or other interfering tissue may be performed. Alternate embodiments could preserve all remaining cartilage.

Both the fully preformed and further formable components could be prepared from any suitable material(s). Typically, the materials include polymeric materials having an optimal combination of such properties as biocompatibility, mechanical strength and durability, and compatibility with other components and/or biomaterials used in the assembly of a final implant. Examples of suitable materials for use in preparing the fully preformed component(s) may be the same or different from the further formable component(s), and include but are not limited to polyurethanes, polyethylene, polypropylene, polyesters, polyethylene terephthalates, polyureas, hydrogels of various chemical natures, metals, ceramics, epoxies, rubber, polyisobutylene, polysiloxanes, polyacrylates, as well as biopolymers, such as collagen or collagen-based materials or the like and combinations thereof. Alternatively device could contain materials that encourage damaged tissue or cartilage growth or that are bioresorbable.

Examples of suitable materials for use in preparing the further formable component, if used, include but are not limited to formable polymers such as polyurethanes, polyimides, polysulfones, polyureas, hydrogels of various chemical natures, polyurethane acrylates, copolymers, block-copolymers, IPN's, mixtures of polymers and other combinations thereof as well as naturally occurring polymers such as chitins, chitosans, elastin, collagens, carbohydrates as cellulose, and the like.

In a presently preferred embodiment, the preformed component(s) and the further formable component(s), if used, each comprises a biocompatible polyurethane. The same or different polyurethane formulations can be used to form the fully preformed component(s), as well as for the further formable component(s).

Suitable polyurethanes for use as either the fully preformed component(s) or further formable component(s) can be prepared by combining: (1) a quasi-prepolymer component comprising the reaction product of one or more hydroxyl or amino containing components such as macrodiols, products of reaction of hydroxyl containing components with difunctional or multifunctional organic acids or isocyanate or other suitable reagents, polyols, and one or more diisocyanates, and optionally, one or more hydrophobic additives or plasticizers or fillers, and (2) a curative component comprising one or more polyols, one or more chain extenders, one or more catalysts, and optionally, other ingredients such as an antioxidant, and hydrophobic additive, or hydrophilic additive.

In a preferred embodiment the fully preformed polyurethane consists of aromatic diisocyanates, polytetramethylene oxide diol(s), chain extender(s), catalyst(s) and antioxidant(s). More preferably it consists of 4,4'-diphenylmethane diisocyanate ("MDI") used either alone or in conjunction with para-phenylene diisocyanate ("PPDI").

In a preferred embodiment the polyurethane prepared from the quasi-prepolymer containing free MDI and isocyanate terminated products of reaction of PPDI and hydroxyl containing components, and does not contain any substantial amount of free PPDI monomer.

In another preferred embodiment the PPDI, or MDI and PPDI, or combination of MDI or PPDI with other di or multifunctional aromatic, aliphatic or cycloaliphatic isocyanate is used to prepare the "true-prepolymer" (i.e. a prepolymer that does not contain any unreacted or free isocyanate monomers). Then, free diisocyanate other than MDI or PPDI is added to form the quasi-prepolymer. The "true" prepolymer can be formed by the reaction of 2 or less equivalents of MDI or PPDI with 1 or more equivalents of the hydroxyl terminated components including polytetramethyleneoxide diols, polycarbonate diols for example (PC-1733, P1667, PC1122 from Stahl), and/or the diols containing both polytetramethyleneoxide and carbonate groups (PolyTHF CD from BASF), or polypropyleneoxide diols, triols or polyols, hydroxyl terminated polybutadiene, hydroxyl terminated hydrogenated polybutadiene, or other suitable hydroxyl terminated components with aliphatic saturated or unsaturated backbone, or combinations thereof.

The formable element of this invention is capable of being changed from its original shape and dimensions in order to provide the exact fit of the device to the unique joint of the particular patient. At the same time, the formable element must provide sufficient dimensional stability for years of the device service life in the physiologic environment, under the physiological loading.

The formability of the element can be achieved by using materials with specific properties such as:

Mixture with the polymer that shows a thermal transition in the temperature range between 45 and 70°C.

Interpenetrating network with the polymer that shows the thermal transition in the temperature range between 45 and 70°C.

Multiphase block copolymer where one of the phases shows thermal transition such as melting in the temperature range between 45 and 70°C.

The component or additive responsible for the formability can be of polymeric or non-polymeric nature, organic or inorganic or a mixture of several components. It also can be monolithic or porous.

The moldability can be also achieved by using the precured but not completely cured device, initially capable of developing permanent deformation under pressure in the joint. The required long-term dimensional stability then achieved as a result of post cure, which may occur in the joint at the body temperature, or using an irradiation (UV, IR) activation mechanism. The post cure of the device can also be completed outside the body by heating the device or use of an irradiation activating mechanism.

The material can be formulated as an interpenetrating network of two or more polymers where at least one of the polymers is fully cured prior to the in-vivo forming step and at least one polymer is post cured after the device is finally shaped.

As an alternative embodiment the moldable element (material) may be used to create a model of the device with perfect fit that then will be used for measurements and making the actual implant outside the body.

20221029 12:01:22




Figure 1




Figure 2




Figure 3






Figure 4

202210-012202-09E6HE09



Anterior



Posterior

Figure 6

Anterior




Figure 7

Lateral

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.